Targeted Therapy of Acute Myeloid Leukemia

Table of Contents

1. Altmetric Badge
   Book Overview
2. Altmetric Badge
   Chapter 1 Genetics and Classification of Acute Myeloid Leukemia
3. Altmetric Badge
   Chapter 2 The Use of “Omics” to Guide the Selection of Targeted Therapy
4. Altmetric Badge
   Chapter 3 Roles of Apoptosis-Regulating Bcl-2 Family Genes in AML
5. Altmetric Badge
   Chapter 4 Bcl-2 Family: Translational Aspects
6. Altmetric Badge
   Chapter 5 IAP Family of Proteins as Therapeutic Targets for Acute Myeloid Leukemia
7. Altmetric Badge
   Chapter 6 TP53 Mutations in Acute Myeloid Leukemia
8. Altmetric Badge
   Chapter 7 Targeting p53 Tumor Suppressor for AML Therapy
9. Altmetric Badge
   Chapter 8 AML-Selective Apoptosis Induction by Rationally Designed Death Ligand Fusion Proteins
10. Altmetric Badge
    Chapter 9 PIM Kinases in AML
11. Altmetric Badge
    Chapter 10 Development of Midostaurin as a Tyrosine Kinase Inhibitor
12. Altmetric Badge
    Chapter 11 FLT3 in AML
13. Altmetric Badge
    Chapter 12 FLT3-ITD. Clinical (Sorafenib/AC220)
14. Altmetric Badge
    Chapter 13 Nucleophosmin (NPM1)
15. Altmetric Badge
    Chapter 14 Raf/MEK/ERK Signaling
16. Altmetric Badge
    Chapter 15 The Role of Translational Medicine in Optimization of Therapies Targeting the RAS-MAP Kinase Pathway
17. Altmetric Badge
    Chapter 16 Clinical Use of Farnesyltransferase Inhibitors
18. Altmetric Badge
    Chapter 17 The PI3K-AKT-mTOR Signaling Network in AML
19. Altmetric Badge
    Chapter 18 Targeting the PI3 Kinase-mTOR Signaling Pathway in AML
20. Altmetric Badge
    Chapter 19 Aurora Kinases
21. Altmetric Badge
    Chapter 20 The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia
22. Altmetric Badge
    Chapter 21 AML: Deacetylases
23. Altmetric Badge
    Chapter 22 Methylation in AML: Clinical Applications
24. Altmetric Badge
    Chapter 23 PML/RARA as the Master Driver of APL Pathogenesis and Therapy Response
25. Altmetric Badge
    Chapter 24 Arsenic Trioxide in Untreated APL
26. Altmetric Badge
    Chapter 25 Targeting PML-RARα with Retinoids
27. Altmetric Badge
    Chapter 26 NR4A Orphan Receptors as Drug Targets
28. Altmetric Badge
    Chapter 27 Antibody-Based Therapeutics Targeting CD33, CD45, and CD66
29. Altmetric Badge
    Chapter 28 New Heterogeneity of the Leukemic Stem Cells
30. Altmetric Badge
    Chapter 29 Targeting Leukemia Stem Cells
31. Altmetric Badge
    Chapter 30 Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling
32. Altmetric Badge
    Chapter 31 CXCR4/CXCL12 as a Therapeutic Target
33. Altmetric Badge
    Chapter 32 VLA-4: A Cell’s Consequential Encounter
34. Altmetric Badge
    Chapter 33 VLA-4 Function and Prognosis in Acute Myeloid Leukemia
35. Altmetric Badge
    Chapter 34 VLA4 in Acute Lymphoblastic Leukemia
36. Altmetric Badge
    Chapter 35 The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia-Activated Prodrugs
37. Altmetric Badge
    Chapter 36 MicroRNAs as Therapeutic Targets
38. Altmetric Badge
    Chapter 37 Clinical Implications of MicroRNAs in AML
39. Altmetric Badge
    Chapter 38 Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias
40. Altmetric Badge
    Chapter 39 Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia Cells
41. Altmetric Badge
    Chapter 40 NK-Cell Immunotherapy for AML
42. Altmetric Badge
    Chapter 41 Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemias
43. Altmetric Badge
    Chapter 42 Indications for Hematopoietic Transplantation for AML
44. Altmetric Badge
    Chapter 43 Mesenchymal Stem/Stromal Cell-Targeted Therapies for Solid Tumors and Hematological Malignancies
45. Altmetric Badge
    Chapter 44 Erratum to: NK-Cell Immunotherapy for AML